SCHEMBL2489645

SCHEMBL2489645

COc1c(C=Cc2ccc(NS(C)(=O)=O)cc2)cc(-c2ccn[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.73
CRBN Q96SW2 1/20 0.38
TRPV1 Q8NER1 2/20 0.35
FYN P06241 2/20 0.33
IKBKB O14920 2/20 0.32
CHUK O15111 2/20 0.32
CYP17A1 P05093 1/20 0.32
ERBB2 P04626 1/20 0.32
SNCA P37840 1/20 0.31
TNFRSF1A P19438 1/20 0.31
PADI4 Q9UM07 1/20 0.31
TGFBR1 P36897 1/20 0.31
ACVR1 Q04771 1/20 0.31
PIP4K2A P48426 1/20 0.31
PIP4K2B P78356 1/20 0.31
JAK2 O60674 1/20 0.30
JAK1 P23458 1/20 0.30
TYK2 P29597 1/20 0.30
JAK3 P52333 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2489644 1.00 CYP3A4 (0.73) CYP3A4CRBNTRPV1FYNIKBKB
SCHEMBL1764839 0.94 CYP3A4 (0.65) CYP3A4CRBNTRPV1FYNIKBKB
SCHEMBL3240242 0.89 CYP3A4 (0.70) CYP3A4CRBNTRPV1FYNCYP17A1
SCHEMBL3240246 0.89 CYP3A4 (0.70) CYP3A4CRBNTRPV1FYNCYP17A1
SCHEMBL2487205 0.87 CYP3A4 (0.56) CYP3A4CRBNFYNCYP17A1
SCHEMBL2487208 0.87 CYP3A4 (0.56) CYP3A4CRBNFYNCYP17A1
SCHEMBL6832451 0.85 CYP3A4 (0.52) CYP3A4ERBB2SNCATNFRSF1A
SCHEMBL1764618 0.85 CYP3A4 (0.65) CYP3A4CRBNTRPV1TNFRSF1APADI4
SCHEMBL1764614 0.85 CYP3A4 (0.65) CYP3A4CRBNTRPV1TNFRSF1APADI4
SCHEMBL2490533 0.85 CYP3A4 (0.54) CYP3A4FYNERBB2SNCATNFRSF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US claimed
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
EP-2379534-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-10-26 EP disclosed
WO-2010072598-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 CYP3A4 978/4885CRBN 1341/4885TRPV1 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.